Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 3
1983 1
2010 1
2012 3
2013 1
2014 1
2015 3
2016 2
2017 3
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Results by year

Filters applied: . Clear all
Page 1
VarWatch-A stand-alone software tool for variant matching.
Fredrich B, Schmöhl M, Junge O, Gundlach S, Ellinghaus D, Pfeufer A, Bettecken T, Siddiqui R, Franke A, Wienker TF, Hoeppner MP, Krawczak M. Fredrich B, et al. Among authors: schmohl m. PLoS One. 2019 Apr 25;14(4):e0215618. doi: 10.1371/journal.pone.0215618. eCollection 2019. PLoS One. 2019. PMID: 31022234 Free PMC article.
Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers.
Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, De Smet M, Gansser D, Norris S, Lang B, Reilly P, Kreuzer J. Glund S, et al. Among authors: schmohl m. J Am Coll Cardiol. 2016 Apr 5;67(13):1654-1656. doi: 10.1016/j.jacc.2016.01.043. J Am Coll Cardiol. 2016. PMID: 27150693 Free article. Clinical Trial. No abstract available.
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.
Glund S, Stangier J, van Ryn J, Schmohl M, Moschetti V, Haazen W, De Smet M, Gansser D, Norris S, Lang B, Reilly P, Kreuzer J. Glund S, et al. Among authors: schmohl m. Clin Pharmacokinet. 2017 Jan;56(1):41-54. doi: 10.1007/s40262-016-0417-0. Clin Pharmacokinet. 2017. PMID: 27317414 Free PMC article. Clinical Trial.
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
Yasaka M, Ikushima I, Harada A, Imazu S, Taniguchi A, Norris S, Gansser D, Stangier J, Schmohl M, Reilly PA. Yasaka M, et al. Among authors: schmohl m. Res Pract Thromb Haemost. 2017 Aug 5;1(2):202-215. doi: 10.1002/rth2.12029. eCollection 2017 Oct. Res Pract Thromb Haemost. 2017. PMID: 30046691 Free PMC article.
19 results